Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-11-02, Stock:NVS, The news for the past five days is as follows:
2020-10-26: NEWS1: Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G).
2020-10-27: NEWS1: Analyst Report: Novartis AG.NEWS2: Novartis Earnings Top, Sales Miss; NVS Stock Falls.NEWS3: Analyst Report: Novartis AG.NEWS4: Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss.NEWS5: Novartis: Q3 Earnings Insights.NEWS6: Novartis upbeat as drugmakers see hospitals coping with COVID.NEWS7: Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance..
2020-10-28: NEWS1: The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts.NEWS2: Novartis Strikes Deal To Commercialize Molecular Partners' COVID-19 Drug Candidates.NEWS3: Molecular Partners jumps after Novartis deal for potential COVID-19 drugs.NEWS4: Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.
2020-10-29: NEWS1: Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?.NEWS2: Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy.NEWS3: The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal.NEWS4: Novartis buys Vedere Bio, whose founders helped blind mice see.NEWS5: CORRECTED-Novartis buys Vedere Bio to boost gene therapy.
2020-10-30: NEWS1: Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study.NEWS2: Pharmaceutical Industry Leaders Target Cutting-Edge MS Treatments That Once Were 'Fantasy'.NEWS3: Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia.

Answer: Rise